Table 2.
Clinical characteristics of the control and CAVD groups.
| Control (n = 197) | CAVD (n = 200) | P | |
|---|---|---|---|
| Age, yrs | 59.02 ± 8.59 | 74.14 ± 7.67 | <0.001 |
| Male, n (%) | 111 (56.3) | 123 (61.5) | NS |
| Body mass index, kg/m2 | 24.65 ± 3.39 | 25.13 ± 3.46 | NS |
| Active smokers, n (%) | 59 (29.9) | 48 (24.0) | NS |
| Alcohol, n (%) | 27 (13.7) | 18 (9.0) | NS |
| Hypertension, n (%) | 127 (64.5) | 154 (77.0) | 0.008 |
| Diabetes, n (%) | 63 (32.0) | 61 (30.5) | NS |
| Coronary heart disease, n (%) | 134 (68.0) | 177 (88.5) | <0.001 |
| Systolic blood pressure, mmHg | 77.07 ± 11.70 | 74.42 ± 11.43 | 0.023 |
| Diastolic blood pressure, mmHg | 131.49 ± 17.73 | 139.78 ± 20.68 | <0.001 |
| Fasting glucose, mmol/L | 5.48 ± 1.86 | 5.52 ± 2.21 | NS |
| HbA1c, % | 6.21 ± 1.167 | 6.38 ± 1.23 | NS |
| Triglycerides, mmol/L | 1.78 ± 1.13 | 1.56 ± 0.86 | 0.025 |
| Total cholesterol, mmol/L | 4.08 ± 1.06 | 3.91 ± 1.19 | NS |
| LDL, mmol/L | 1.13 ± 0.26 | 1.07 ± 0.29 | 0.044 |
| HDL, mmol/L | 2.39 ± 0.88 | 2.32 ± 0.98 | NS |
| Lipoprotein(a), g/L | 0.12 (0.20) | 0.14 (0.30) | 0.026 |
| γ-Glutamyl transpeptidase, U/L | 19.00 (20.00) | 21.00 (14.00) | NS |
| Blood urea nitrogen, mmol/L | 5.06 ± 1.29 | 6.03 ± 2.40 | <0.001 |
| Creatinine, mmol/L | 74.07 ± 16.07 | 86.38 ± 24.25 | <0.001 |
| eGFR(CKD-EPI), mL/min | 90.39 ± 17.62 | 72.29 ± 18.23 | <0.001 |
| Peak aortic transvalvular velocity, m/s | 2.10 ± 0.21 | 2.14 ± 0.22 | NS |
| Systolic pulmonary artery pressure, mmHg | 34.81 ± 2.25 | 35.21 ± 1.98 | NS |
| Aortic valve mean gradient, mmHg | 4.51 ± 1.01 | 4.72 ± 1.12 | NS |
| Metformin, n (%) | 35 (17.8) | 28 (14.0) | NS |
| Statin, n (%) | 163 (82.7) | 167 (83.5) | NS |
| GLP-1, pmol/L | 14.00 (9.68) | 11.29 (6.75) | <0.001 |
Values are expressed as the mean ± SD, number (%), or median (interquartile range).
CAVD, calcific aortic valve disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, not significant.